Karine Breckpot
Overview
Explore the profile of Karine Breckpot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
4739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dewulf J, Massa S, Navarro L, Dekempeneer Y, Santens F, Ceuppens H, et al.
J Nanobiotechnology
. 2024 Dec;
22(1):763.
PMID: 39696571
Background: Folate receptor alpha (FRα) overexpression is seen in many cancers. Radioligand therapy (RLT) has emerged as a promising tool to target FRα and has been investigated previously, but further...
2.
Meeus F, Funeh C, Awad R, Zeven K, Autaers D, De Becker A, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39562005
Background: Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of...
3.
Vandewalle N, De Beule N, De Becker A, de Bruyne E, Menu E, Vanderkerken K, et al.
Exp Hematol Oncol
. 2024 Oct;
13(1):99.
PMID: 39367387
Until recently, treatment options for patients diagnosed with Acute Myeloid Leukemia (AML) were limited and predominantly relied on various combinations, dosages, or schedules of traditional chemotherapeutic agents. Patients with advanced...
4.
Engelen Y, Krysko D, Effimova I, Breckpot K, Versluis M, De Smedt S, et al.
J Control Release
. 2024 Sep;
375:389-403.
PMID: 39293525
Over the past decade, ultrasound (US) has gathered significant attention and research focus in the realm of medical treatments, particularly within the domain of anti-cancer therapies. This growing interest can...
5.
Ceuppens H, Pombo Antunes A, Navarro L, Ertveldt T, Berdal M, Nagachinta S, et al.
Eur J Nucl Med Mol Imaging
. 2024 Sep;
52(2):444-457.
PMID: 39237746
Purpose: Targeted radionuclide therapy (TRT) is a cancer treatment with relative therapeutic efficacy across various cancer types. We studied the therapeutic potential of TRT using fibroblast activation protein-α (FAP) targeting...
6.
Dierick H, Navarro L, Ceuppens H, Ertveldt T, Pombo Antunes A, Keyaerts M, et al.
EJNMMI Radiopharm Chem
. 2024 Jul;
9(1):54.
PMID: 39048805
Background: Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[F]fluorobenzoate ([F]SFB) has shown to be a promising strategy in the development of sdAb-based PET tracers. While automation of the prosthetic group...
7.
Van der Vreken A, Vanderkerken K, de Bruyne E, de Veirman K, Breckpot K, Menu E
Exp Hematol Oncol
. 2024 Jul;
13(1):66.
PMID: 38987856
CAR T cells are widely applied for relapsed hematological cancer patients. With six approved cell therapies, for Multiple Myeloma and other B-cell malignancies, new insights emerge. Profound evidence shows that...
8.
Hanssens H, Meeus F, Gesquiere E, Puttemans J, De Vlaeminck Y, de Veirman K, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38891821
CAR-T cell therapy is at the forefront of next-generation multiple myeloma (MM) management, with two B-cell maturation antigen (BCMA)-targeted products recently approved. However, these products are incapable of breaking the...
9.
Mateusiak L, Floru S, De Groof T, Wouters J, Declerck N, Debie P, et al.
Adv Sci (Weinh)
. 2024 Jun;
11(30):e2400700.
PMID: 38845188
Fluorescence molecular imaging plays a vital role in image-guided surgery. In this context, the urokinase plasminogen activator receptor (uPAR) is an interesting biomarker enabling the detection and delineation of various...
10.
Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof T, et al.
Theranostics
. 2024 May;
14(7):2656-2674.
PMID: 38773967
AXL expression has been identified as a prognostic factor in acute myeloid leukemia (AML) and is detectable in approximately 50% of AML patients. In this study, we developed AXL-specific single...